Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

September 06, 2024

Vol.50 No.33

Drugs & Targets

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

September 06, 2024

Vol.50 No.33

Drugs & Targets

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

Daiichi Sankyo and Merck have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 targeting T-cell engager.

August 09, 2024

Vol.50 No.32

Drugs & Targets

CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

Genentech, a member of the Roche Group, announced that the phase II/III SKYSCRAPER-06 study evaluating tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 [95% CI: 1.02,1.57] and overall survival at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature.

July 12, 2024

Vol.50 No.28

Clinical Roundup

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute researchers have found a potentially effective drug-combination approach to treating certain patients with non-small cell lung cancer.

June 28, 2024

Vol.50 No.26

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

YOU MAY BE INTERESTED IN

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC

Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager

CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma

Tiragolumab + atezolizumab for metastatic nSq NSCLC did not meet primary endpoints in phase II/III trial

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login